Business
Archived — This article has been archived. The information may be outdated.
USFDA issues 2 observations at Dr Reddy's Mexico plant
The Hindu BusinessLine··12 Sept
Dr Reddy's Laboratories said U.S. FDA officials completed a records assessment of its API plant in Mexico and issued two observations on Form FDA 2953. The review at Industrias Químicas Falcon de México ran from July 17 to September 8, the company said Friday. Dr Reddy's said it will respond within the stipulated timeline without disclosing observation details.
Prism
What It Means For You
- API buyers may request updated compliance letters before renewing supply contracts.
- Form 2953 observations can trigger corrective action plans at manufacturing sites.
- Regulatory filings often move share prices when investors parse FDA language.
What's Happening
- The assessment examined documentation rather than a full on-site inspection.
- Dr Reddy's did not disclose the observation details in its filing.
- Records assessments evaluate whether plant paperwork meets U.S. rules.
FDA Mexico API review
- The facility makes active pharmaceutical ingredients in Mexico.
- FDA Form 2953 is used to communicate records-review findings.
- Dr Reddy's is a major Indian pharmaceutical exporter to the U.S.
all-news
